Skip to main content
Top
Published in: Journal of Neuroinflammation 1/2014

Open Access 01-12-2014 | Research

The temporal dynamics of plasma fractalkine levels in ischemic stroke: association with clinical severity and outcome

Authors: Gerrit M Grosse, Anita B Tryc, Meike Dirks, Ramona Schuppner, Henning Pflugrad, Ralf Lichtinghagen, Karin Weissenborn, Hans Worthmann

Published in: Journal of Neuroinflammation | Issue 1/2014

Login to get access

Abstract

Background

The chemokine fractalkine (CX3CL1, FKN) is involved in neural-microglial interactions and is regarded as neuroprotective according to several in vivo studies of inflammatory and degenerative states of the brain. Recently, an association with outcome in human ischemic stroke has been proposed. In this study, we aimed to investigate the temporal pattern of FKN levels in acute ischemic stroke in relation to stroke severity and outcome.

Methods

FKN levels were measured in plasma specimens of fifty-five patients with acute ischemic stroke. Blood was available for time points 6 hours (h), 12 h, 3 days (d), 7 d and 90 d after stroke onset. Clinical outcome was evaluated using the modified Rankin Scale (mRS) at 7 d and 90 d.

Results

The time course of FKN significantly differs depending on stroke severity, with higher FKN levels linked to a lower severity. FKN levels in patients with moderate to severe strokes differ significantly from controls. In outcome analysis, we found an association of dynamics of FKN with clinical outcome. Decrease of FKN is pronounced in patients with worse outcome. Multivariate analysis including stroke severity and stroke etiology revealed that deltaFKN between 6 h and 3 d is independently associated with mRS at 90 d. In addition deltaFKN is inversely correlated with the extent of brain damage, as measured by S100B.

Conclusions

FKN dynamics are independently associated with stroke outcome. Further studies might give insight on whether FKN is actively involved in the inflammatory cascade after acute ischemic stroke.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ: A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997, 385: 640-644. 10.1038/385640a0.CrossRefPubMed Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ: A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997, 385: 640-644. 10.1038/385640a0.CrossRefPubMed
2.
go back to reference Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K, Hartmann D, Fahrenholz F, Postina R, Matthews V, Kallen K-J, Rose-John S, Ludwig A: The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood. 2003, 102: 1186-1195. 10.1182/blood-2002-12-3775.CrossRefPubMed Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K, Hartmann D, Fahrenholz F, Postina R, Matthews V, Kallen K-J, Rose-John S, Ludwig A: The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood. 2003, 102: 1186-1195. 10.1182/blood-2002-12-3775.CrossRefPubMed
3.
go back to reference Matsunawa M, Isozaki T, Odai T, Yajima N, Takeuchi HT, Negishi M, Ide H, Adachi M, Kasama T: Increased serum levels of soluble fractalkine (CX3CL1) correlate with disease activity in rheumatoid vasculitis. Arthritis Rheum. 2006, 54: 3408-3416. 10.1002/art.22208.CrossRefPubMed Matsunawa M, Isozaki T, Odai T, Yajima N, Takeuchi HT, Negishi M, Ide H, Adachi M, Kasama T: Increased serum levels of soluble fractalkine (CX3CL1) correlate with disease activity in rheumatoid vasculitis. Arthritis Rheum. 2006, 54: 3408-3416. 10.1002/art.22208.CrossRefPubMed
4.
go back to reference Lee S, Varvel NH, Konerth ME, Xu G, Cardona AE, Ransohoff RM, Lamb BT: CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer’s disease mouse models. Am J Pathol. 2010, 177: 2549-2562. 10.2353/ajpath.2010.100265.PubMedCentralCrossRefPubMed Lee S, Varvel NH, Konerth ME, Xu G, Cardona AE, Ransohoff RM, Lamb BT: CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer’s disease mouse models. Am J Pathol. 2010, 177: 2549-2562. 10.2353/ajpath.2010.100265.PubMedCentralCrossRefPubMed
5.
go back to reference Pabon MM, Bachstetter AD, Hudson CE, Gemma C, Bickford PC: CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease. J Neuroinflammation. 2011, 8: 9-10.1186/1742-2094-8-9.PubMedCentralCrossRefPubMed Pabon MM, Bachstetter AD, Hudson CE, Gemma C, Bickford PC: CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease. J Neuroinflammation. 2011, 8: 9-10.1186/1742-2094-8-9.PubMedCentralCrossRefPubMed
6.
go back to reference Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, McNamara RK, Streit WJ, Salafranca MN, Adhikari S, Thompson DA, Botti P, Bacon KB, Feng L: Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci U S A. 1998, 95: 10896-10901. 10.1073/pnas.95.18.10896.PubMedCentralCrossRefPubMed Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, McNamara RK, Streit WJ, Salafranca MN, Adhikari S, Thompson DA, Botti P, Bacon KB, Feng L: Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci U S A. 1998, 95: 10896-10901. 10.1073/pnas.95.18.10896.PubMedCentralCrossRefPubMed
7.
go back to reference Nishiyori A, Minami M, Ohtani Y, Takami S, Yamamoto J, Kawaguchi N, Kume T, Akaike A, Satoh M: Localization of fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia?. FEBS Lett. 1998, 429: 167-172. 10.1016/S0014-5793(98)00583-3.CrossRefPubMed Nishiyori A, Minami M, Ohtani Y, Takami S, Yamamoto J, Kawaguchi N, Kume T, Akaike A, Satoh M: Localization of fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia?. FEBS Lett. 1998, 429: 167-172. 10.1016/S0014-5793(98)00583-3.CrossRefPubMed
8.
go back to reference Maciejewski-Lenoir D, Chen S, Feng L, Maki R, Bacon KB: Characterization of fractalkine in rat brain cells: migratory and activation signals for CX3CR-1-expressing microglia. J Immunol. 1999, 163: 1628-1635.PubMed Maciejewski-Lenoir D, Chen S, Feng L, Maki R, Bacon KB: Characterization of fractalkine in rat brain cells: migratory and activation signals for CX3CR-1-expressing microglia. J Immunol. 1999, 163: 1628-1635.PubMed
9.
go back to reference Cipriani R, Villa P, Chece G, Lauro C, Paladini A, Micotti E, Perego C, De Simoni MG, Fredholm BB, Eusebi F, Limatola C: CX3CL1 is neuroprotective in permanent focal cerebral ischemia in rodents. J Neurosci. 2011, 31: 16327-16335. 10.1523/JNEUROSCI.3611-11.2011.CrossRefPubMed Cipriani R, Villa P, Chece G, Lauro C, Paladini A, Micotti E, Perego C, De Simoni MG, Fredholm BB, Eusebi F, Limatola C: CX3CL1 is neuroprotective in permanent focal cerebral ischemia in rodents. J Neurosci. 2011, 31: 16327-16335. 10.1523/JNEUROSCI.3611-11.2011.CrossRefPubMed
10.
go back to reference Denes A, Ferenczi S, Halasz J, Kornyei Z, Kovacs KJ, Dénes A, Halász J, Környei Z, Kovács KJ: Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. J Cereb Blood Flow Metab. 2008, 28: 1707-1721. 10.1038/jcbfm.2008.64.CrossRefPubMed Denes A, Ferenczi S, Halasz J, Kornyei Z, Kovacs KJ, Dénes A, Halász J, Környei Z, Kovács KJ: Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. J Cereb Blood Flow Metab. 2008, 28: 1707-1721. 10.1038/jcbfm.2008.64.CrossRefPubMed
11.
go back to reference Soriano SG, Amaravadi LS, Wang YF, Zhou H, Yu GX, Tonra JR, Fairchild-Huntress V, Fang Q, Dunmore JH, Huszar D, Pan Y: Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. J Neuroimmunol. 2002, 125: 59-65.CrossRefPubMed Soriano SG, Amaravadi LS, Wang YF, Zhou H, Yu GX, Tonra JR, Fairchild-Huntress V, Fang Q, Dunmore JH, Huszar D, Pan Y: Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. J Neuroimmunol. 2002, 125: 59-65.CrossRefPubMed
12.
go back to reference Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, Huang D, Kidd G, Dombrowski S, Dutta R, Lee J-CC, Cook DN, Jung S, Lira SA, Littman DR, Ransohoff RM: Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci. 2006, 9: 917-924. 10.1038/nn1715.CrossRefPubMed Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, Huang D, Kidd G, Dombrowski S, Dutta R, Lee J-CC, Cook DN, Jung S, Lira SA, Littman DR, Ransohoff RM: Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci. 2006, 9: 917-924. 10.1038/nn1715.CrossRefPubMed
13.
go back to reference Sunnemark D, Eltayeb S, Nilsson M, Wallström E, Lassmann H, Olsson T, Berg A-L, Ericsson-Dahlstrand A: CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin. J Neuroinflammation. 2005, 2: 17-10.1186/1742-2094-2-17.PubMedCentralCrossRefPubMed Sunnemark D, Eltayeb S, Nilsson M, Wallström E, Lassmann H, Olsson T, Berg A-L, Ericsson-Dahlstrand A: CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin. J Neuroinflammation. 2005, 2: 17-10.1186/1742-2094-2-17.PubMedCentralCrossRefPubMed
14.
go back to reference Donohue MM, Cain K, Zierath D, Shibata D, Tanzi PM, Becker KJ: Higher plasma fractalkine is associated with better 6-month outcome from ischemic stroke. Stroke. 2012, 43: 2300-2306. 10.1161/STROKEAHA.112.657411.PubMedCentralCrossRefPubMed Donohue MM, Cain K, Zierath D, Shibata D, Tanzi PM, Becker KJ: Higher plasma fractalkine is associated with better 6-month outcome from ischemic stroke. Stroke. 2012, 43: 2300-2306. 10.1161/STROKEAHA.112.657411.PubMedCentralCrossRefPubMed
15.
go back to reference Worthmann H, Tryc AB, Goldbecker A, Ma YT, Tountopoulou A, Hahn A, Dengler R, Lichtinghagen R, Weissenborn K: The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome. Cerebrovasc Dis. 2010, 30: 85-92. 10.1159/000314624.CrossRefPubMed Worthmann H, Tryc AB, Goldbecker A, Ma YT, Tountopoulou A, Hahn A, Dengler R, Lichtinghagen R, Weissenborn K: The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome. Cerebrovasc Dis. 2010, 30: 85-92. 10.1159/000314624.CrossRefPubMed
16.
go back to reference Coutts SB, Barber PA, Demchuk AM, Hill MD, Pexman JHW, Hudon ME, Buchan AM: Mild neurological symptoms despite middle cerebral artery occlusion. Stroke. 2004, 35: 469-471. 10.1161/01.STR.0000110985.01773.7F.CrossRefPubMed Coutts SB, Barber PA, Demchuk AM, Hill MD, Pexman JHW, Hudon ME, Buchan AM: Mild neurological symptoms despite middle cerebral artery occlusion. Stroke. 2004, 35: 469-471. 10.1161/01.STR.0000110985.01773.7F.CrossRefPubMed
17.
go back to reference Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D, Investigators E: Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008, 359: 1317-1329. 10.1056/NEJMoa0804656.CrossRefPubMed Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D, Investigators E: Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008, 359: 1317-1329. 10.1056/NEJMoa0804656.CrossRefPubMed
18.
go back to reference Dengler R, Diener HC, Schwartz A, Grond M, Schumacher H, Machnig T, Eschenfelder CC, Leonard J, Weissenborn K, Kastrup A, Haberl R, Investigators E: Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2010, 9: 159-166. 10.1016/S1474-4422(09)70361-8.CrossRefPubMed Dengler R, Diener HC, Schwartz A, Grond M, Schumacher H, Machnig T, Eschenfelder CC, Leonard J, Weissenborn K, Kastrup A, Haberl R, Investigators E: Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2010, 9: 159-166. 10.1016/S1474-4422(09)70361-8.CrossRefPubMed
19.
go back to reference Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993, 24: 35-41. 10.1161/01.STR.24.1.35.CrossRefPubMed Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993, 24: 35-41. 10.1161/01.STR.24.1.35.CrossRefPubMed
20.
go back to reference Mizuno T, Kawanokuchi J, Numata K, Suzumura A: Production and neuroprotective functions of fractalkine in the central nervous system. Brain Res. 2003, 979: 65-70. 10.1016/S0006-8993(03)02867-1.CrossRefPubMed Mizuno T, Kawanokuchi J, Numata K, Suzumura A: Production and neuroprotective functions of fractalkine in the central nervous system. Brain Res. 2003, 979: 65-70. 10.1016/S0006-8993(03)02867-1.CrossRefPubMed
21.
go back to reference Zujovic V, Benavides J, Vigé X, Carter C, Taupin V: Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation. Glia. 2000, 29: 305-315. 10.1002/(SICI)1098-1136(20000215)29:4<305::AID-GLIA2>3.0.CO;2-V.CrossRefPubMed Zujovic V, Benavides J, Vigé X, Carter C, Taupin V: Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation. Glia. 2000, 29: 305-315. 10.1002/(SICI)1098-1136(20000215)29:4<305::AID-GLIA2>3.0.CO;2-V.CrossRefPubMed
22.
go back to reference Boehme SA, Lio FM, Maciejewski-Lenoir D, Bacon KB, Conlon PJ: The chemokine fractalkine inhibits Fas-mediated cell death of brain microglia. J Immunol. 2000, 165: 397-403. 10.4049/jimmunol.165.1.397.CrossRefPubMed Boehme SA, Lio FM, Maciejewski-Lenoir D, Bacon KB, Conlon PJ: The chemokine fractalkine inhibits Fas-mediated cell death of brain microglia. J Immunol. 2000, 165: 397-403. 10.4049/jimmunol.165.1.397.CrossRefPubMed
23.
go back to reference Meucci O, Fatatis A, Simen AA, Miller RJ: Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival. Proc Natl Acad Sci U S A. 2000, 97: 8075-8080. 10.1073/pnas.090017497.PubMedCentralCrossRefPubMed Meucci O, Fatatis A, Simen AA, Miller RJ: Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival. Proc Natl Acad Sci U S A. 2000, 97: 8075-8080. 10.1073/pnas.090017497.PubMedCentralCrossRefPubMed
24.
go back to reference Gelderblom M, Leypoldt F, Steinbach K, Behrens D, Choe CU, Siler DA, Arumugam TV, Orthey E, Gerloff C, Tolosa E, Magnus T: Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke. 2009, 40: 1849-1857. 10.1161/STROKEAHA.108.534503.CrossRefPubMed Gelderblom M, Leypoldt F, Steinbach K, Behrens D, Choe CU, Siler DA, Arumugam TV, Orthey E, Gerloff C, Tolosa E, Magnus T: Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke. 2009, 40: 1849-1857. 10.1161/STROKEAHA.108.534503.CrossRefPubMed
25.
go back to reference Grønberg NV, Johansen FF, Kristiansen U, Hasseldam H: Leukocyte infiltration in experimental stroke. J Neuroinflammation. 2013, 10: 115-10.1186/1742-2094-10-115.PubMedCentralCrossRefPubMed Grønberg NV, Johansen FF, Kristiansen U, Hasseldam H: Leukocyte infiltration in experimental stroke. J Neuroinflammation. 2013, 10: 115-10.1186/1742-2094-10-115.PubMedCentralCrossRefPubMed
26.
go back to reference Urra X, Villamor N, Amaro S, Gomez-Choco M, Obach V, Oleaga L, Planas AM, Chamorro A: Monocyte subtypes predict clinical course and prognosis in human stroke. J Cereb Blood Flow Metab. 2009, 29: 994-1002. 10.1038/jcbfm.2009.25.CrossRefPubMed Urra X, Villamor N, Amaro S, Gomez-Choco M, Obach V, Oleaga L, Planas AM, Chamorro A: Monocyte subtypes predict clinical course and prognosis in human stroke. J Cereb Blood Flow Metab. 2009, 29: 994-1002. 10.1038/jcbfm.2009.25.CrossRefPubMed
27.
go back to reference Bao Y, Kim E, Bhosle S, Mehta H, Cho S: A role for spleen monocytes in post-ischemic brain inflammation and injury. J Neuroinflammation. 2010, 7: 92-10.1186/1742-2094-7-92.PubMedCentralCrossRefPubMed Bao Y, Kim E, Bhosle S, Mehta H, Cho S: A role for spleen monocytes in post-ischemic brain inflammation and injury. J Neuroinflammation. 2010, 7: 92-10.1186/1742-2094-7-92.PubMedCentralCrossRefPubMed
28.
go back to reference Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, Libby P, Weissleder R, Pittet MJ: The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 2007, 204: 3037-3047. 10.1084/jem.20070885.PubMedCentralCrossRefPubMed Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, Libby P, Weissleder R, Pittet MJ: The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 2007, 204: 3037-3047. 10.1084/jem.20070885.PubMedCentralCrossRefPubMed
29.
go back to reference Nahrendorf M, Pittet MJ, Swirski FK: Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circulation. 2010, 121: 2437-2445. 10.1161/CIRCULATIONAHA.109.916346.PubMedCentralCrossRefPubMed Nahrendorf M, Pittet MJ, Swirski FK: Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circulation. 2010, 121: 2437-2445. 10.1161/CIRCULATIONAHA.109.916346.PubMedCentralCrossRefPubMed
30.
go back to reference Stolla M, Pelisek J, von Bruhl ML, Schafer A, Barocke V, Heider P, Lorenz M, Tirniceriu A, Steinhart A, Bauersachs J, Bray PF, Massberg S, Schulz C, von Brühl M-L, Schäfer A: Fractalkine is expressed in early and advanced atherosclerotic lesions and supports monocyte recruitment via CX3CR1. PLoS One. 2012, 7: e43572-10.1371/journal.pone.0043572.PubMedCentralCrossRefPubMed Stolla M, Pelisek J, von Bruhl ML, Schafer A, Barocke V, Heider P, Lorenz M, Tirniceriu A, Steinhart A, Bauersachs J, Bray PF, Massberg S, Schulz C, von Brühl M-L, Schäfer A: Fractalkine is expressed in early and advanced atherosclerotic lesions and supports monocyte recruitment via CX3CR1. PLoS One. 2012, 7: e43572-10.1371/journal.pone.0043572.PubMedCentralCrossRefPubMed
31.
go back to reference Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, Garin A, Liu J, Mack M, van Rooijen N, Lira SA, Habenicht AJ, Randolph GJ: Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest. 2007, 117: 185-194. 10.1172/JCI28549.PubMedCentralCrossRefPubMed Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, Garin A, Liu J, Mack M, van Rooijen N, Lira SA, Habenicht AJ, Randolph GJ: Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest. 2007, 117: 185-194. 10.1172/JCI28549.PubMedCentralCrossRefPubMed
32.
go back to reference Wong BW, Wong D, McManus BM: Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardiovasc Pathol. 2002, 11: 332-338. 10.1016/S1054-8807(02)00111-4.CrossRefPubMed Wong BW, Wong D, McManus BM: Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardiovasc Pathol. 2002, 11: 332-338. 10.1016/S1054-8807(02)00111-4.CrossRefPubMed
33.
go back to reference Combadiere C, Potteaux S, Gao JL, Esposito B, Casanova S, Lee EJ, Debre P, Tedgui A, Murphy PM, Mallat Z: Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation. 2003, 107: 1009-1016. 10.1161/01.CIR.0000057548.68243.42.CrossRefPubMed Combadiere C, Potteaux S, Gao JL, Esposito B, Casanova S, Lee EJ, Debre P, Tedgui A, Murphy PM, Mallat Z: Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation. 2003, 107: 1009-1016. 10.1161/01.CIR.0000057548.68243.42.CrossRefPubMed
34.
go back to reference Lesnik P, Haskell CA, Charo IF: Decreased atherosclerosis in CX3 CR1-/-mice reveals a role for fractalkine in atherogenesis. J Clin Invest. 2003, 111: 333-340. 10.1172/JCI15555.PubMedCentralCrossRefPubMed Lesnik P, Haskell CA, Charo IF: Decreased atherosclerosis in CX3 CR1-/-mice reveals a role for fractalkine in atherogenesis. J Clin Invest. 2003, 111: 333-340. 10.1172/JCI15555.PubMedCentralCrossRefPubMed
35.
go back to reference Saederup N, Chan L, Lira SA, Charo IF: Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/-mice: evidence for independent chemokine functions in atherogenesis. Circulation. 2008, 117: 1642-1648. 10.1161/CIRCULATIONAHA.107.743872.PubMedCentralCrossRefPubMed Saederup N, Chan L, Lira SA, Charo IF: Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/-mice: evidence for independent chemokine functions in atherogenesis. Circulation. 2008, 117: 1642-1648. 10.1161/CIRCULATIONAHA.107.743872.PubMedCentralCrossRefPubMed
36.
go back to reference Richter B, Koller L, Hohensinner PJ, Rychli K, Zorn G, Goliasch G, Berger R, Mortl D, Maurer G, Huber K, Pacher R, Wojta J, Hulsmann M, Niessner A: Fractalkine is an independent predictor of mortality in patients with advanced heart failure. Thromb Haemost. 2012, 108: 1220-1227. 10.1160/TH12-03-0195.CrossRefPubMed Richter B, Koller L, Hohensinner PJ, Rychli K, Zorn G, Goliasch G, Berger R, Mortl D, Maurer G, Huber K, Pacher R, Wojta J, Hulsmann M, Niessner A: Fractalkine is an independent predictor of mortality in patients with advanced heart failure. Thromb Haemost. 2012, 108: 1220-1227. 10.1160/TH12-03-0195.CrossRefPubMed
Metadata
Title
The temporal dynamics of plasma fractalkine levels in ischemic stroke: association with clinical severity and outcome
Authors
Gerrit M Grosse
Anita B Tryc
Meike Dirks
Ramona Schuppner
Henning Pflugrad
Ralf Lichtinghagen
Karin Weissenborn
Hans Worthmann
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2014
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/1742-2094-11-74

Other articles of this Issue 1/2014

Journal of Neuroinflammation 1/2014 Go to the issue